Dr. Matthew S. Davids, MD

Dr. Davids practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Davids' NPI, 1659541522, was assigned on March 7, 2008. Dr. Davids graduated from Yale School of Medicine in 2005. Dr. Davids holds Massachusetts license 234844.

Dr. Davids' primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Davids' primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Davids is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Davids to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Davids practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Davids' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Davids is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Davids' licenses on file in 3 states: Massachusetts, Connecticut and New York.

Dmand AI lists breast cancer, chronic leukemia, lymphoma and prostate cancer among the conditions Dr. Davids treats.

CMS data shows 376 Medicare services from Dr. Davids across 5 procedure codes in 2024, for 238 Medicare patients. Medicare paid $30,819 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 238 Medicare patients who saw Dr. Davids in 2024. The largest group is 75 to 84, with 108 patients. 66% of them have high cholesterol, and 59% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Davids' median patient age at 73, with 44% women.

In 2024, Dr. Davids wrote 120 Medicare Part D claims for 25 patients. 43% of them were for generic drugs. CMS names the drug for 53 of them, across 4 drugs with 11 or more claims each, at $794,752 in total drug cost. In 2023, CMS named 62 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Davids for performance year 2024, reported as part of a group. Dr. Davids accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Davids as offering telehealth.

Dmand AI links 243 papers to Dr. Davids, published from 2009 to 2025. 2018 was the busiest year, with 19. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic and Sulfonamides. Dr. Davids has published most often in Blood. Dr. Davids' most frequent co-authors are Ann S. Lacasce, MD, David Christopher Fisher, MD and Philippe Armand, MD, PhD.

Dmand AI links Dr. Davids to 14 clinical trials, 6 of them phase 1 studies. 10 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Leukemia, Lymphoid. Dana-Farber Cancer Institute sponsors the most, 8. Open Payments lists research payments to Dr. Davids that name 3 trials.

CMS Open Payments shows 620 general payments to Dr. Davids from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Abbvie Inc. paid the most, $247,130. It also lists 15 research payments totaling $54,711 from 2016 to 2025, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Davids, most recently Young Scientist Award in 2012.

Dr. Davids graduated from Yale School of Medicine in 2005. Dr. Davids is a member of ASCO.

Dr. Davids is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.